Ongoing serious, non-healing wound, ulcer, or bone fracture
History of serious or non-healing wound, ulcer, or bone fracture
Serious or non-healing wound, skin ulcer, or bone fracture
Prior osteoporotic fracture
Serious nonhealing wound, ulcer, or bone fracture
Serious non-healing wound, ulcer, or bone fracture within 6 months prior to enrollment
Patients who have undergone major surgery or trauma within 28 days prior to the first dose of investigational product and/or present with any non-healing wound, fracture, or ulcer are NOT eligible for participation; procedures such as catheter placement not considered to be major surgery
Major surgery or trauma within 28 days prior to first dose of investigational product and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major surgery)
Serious, non-healing wound, active ulcer, or untreated bone fracture
Serious, non-healing wound, ulcer, or bone fracture.
Evidence of a significant uncontrolled concomitant disease of the nervous system, pulmonary, autoimmune, renal, hepatic, endocrine, or gastrointestinal disorders; or a serious non-healing wound or fracture
Serious or non-healing wound, peptic ulcer, or bone fracture within 28 days prior to initiation of study treatment;
Patients with serious or non-healing wound, ulcer, or bone fracture
Prior major surgery or fracture within 3 weeks prior to randomization or presence of any non-healing wound.
Patients with a serious or nonhealing wound, ulcer, or bone fracture within 28 days prior to enrollment
Serious or non-healing wound, ulcer, or bone fracture.
Presence of a non-healing wound, or non-healing ulcer, (that is not tumor related) or bone fracture
Any patient with a current non-healing wound, bone fracture, or skin ulcer is excluded
Patients with serious non-healing wound, ulcer, or bone factor; patients with granulating incisions healing by secondary intention with no evidence of fascial dehiscence or infection are eligible but require weekly wound examinations
Presence of serious or nonhealing wound, ulcer, or bone fracture within 28 days prior to enrollment
Serious, non-healing wound; active ulcer; or untreated bone fracture
Presence of any non-healing wound, fracture, or ulcer within 28 days prior to study registration.
Patients with serious or non-healing wound, ulcer, or bone fracture.
Patients who have non-healing wound, unhealed or incompletely healed fracture, or a compound (open) bone fracture at the time of enrollment are not eligible
Other clinically significant disorders such as:\r\n* Active infection requiring systemic treatment within 28 days before the first dose of study treatment; participants with HIV infection will be eligible provided they meet the criteria; participants with known hepatitis B infection should be screened for active disease prior to study participation; participants with known hepatitis C infection must not be actively receiving treatment for the infection\r\n* Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment\r\n* History of organ transplant\r\n* Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment\r\n* History of major surgery as follows:\r\n** Major surgery within 3 months of the first dose of cabozantinib if there were no wound healing complications or within 6 months of the first dose of cabozantinib if there were wound complications\r\n** Minor surgery within 1 month of the first dose of cabozantinib if there were no wound healing complications or within 3 months of the first dose of cabozantinib if there were wound complications\r\n* In addition, complete wound healing from prior surgery must be confirmed at least 28 days before the first dose of cabozantinib irrespective of the time from surgery
Ongoing serious, non-healing wound, ulcer, or bone fracture.
Have active poor wound healing (delayed healing, wound infection or fistula)
Patients with a serious non-healing wound, active ulcer, or untreated bone fracture
Presence of non-healing wound, non-healing ulcer, or bone fracture
Presence of a non-healing wound, non-healing ulcer, or bone fracture
Presence of a non-healing wound, non-healing ulcer, or bone fracture
Any severe or poorly controlled systemic disease (e.g., hypertension; clinically significant cardiovascular, pulmonary, or metabolic disease, disorders of wound healing, ulcer or bone fracture)
Serious, non-healing wound, ulcer, or bone fracture
Serious, non-healing wound or ulcer; bone fracture within 3 months prior to study entry
Serious or non-healing wound, ulcer or bone fracture
History or evidence of arterial thrombotic or hemorrhagic disorders within 3 months before proposed start of treatment, non-healing wound, ulcer, or bone fracture
Patients who have a non-healing wound, ulcer, or bone fracture.
Serious non-healing wound, ulcer or bone fracture
Serious, non-healing wound, active ulcer, or untreated bone fracture.
Non-healing wound, ulcer, non-healing traumatic bone fracture, or abscess within 30 days of enrollment\r\n* Nondisplaced, uncomplicated pathologic fracture due to tumor may be eligible provided adequately treated with radiation, surgery or other treatments with full recovery based upon investigator assessment
Has a known history of non-healing wounds or ulcers, or bone re-fractures within 3 months of fracture
Non-healing wound(s) or ulcer(s) except for ulcerative lesions caused by the underlying neoplasm;
Serious, non-healing wound, ulcer, or bone fracture
Serious, non-healing wound, ulcer, or bone fracture.
Serious non-healing wound, ulcer or bone fracture
Non-healing wound, ulcer, or bone fracture
Patients who have serious, non-healing wound, ulcer, or bone fracture
Serious, non-healing wound, ulcer, or bone fracture.
have any non-healing wound, fracture, or ulcer within 28 days prior to the planned start of study treatment;
(Bevacizumab-related exclusion) History of abdominal fistula or gastrointestinal perforation within 6 months prior to the first study treatment. Serious, non-healing wound, active ulcer, or untreated bone fracture (adjuvant trials: bone fractures must be healed)
Serious non-healing or dehiscing wound, active ulcer, or untreated or non-healing bone fracture
FOR ALL PHASES (Ib AND II): Non-healing wound or ulcer
Major surgery or trauma within 28 days prior to first dose of investigational product and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement are not considered to be major surgery)
Presence of a non-healing wound, non-healing ulcer, or bone fracture
Serious or non-healing wound, ulcer, or bone fracture.
Serious, non-healing wound, active ulcer, or untreated bone fracture, including tumor-related pathological fracture
Presence of a non-healing wound, non-healing ulcer or bone fracture
History of abdominal fistula or gastrointestinal perforation =< 6 months before cycle 1, day 1; serious non-healing wound, active ulcer, or untreated bone fracture (adjuvant trials: bone fractures must be healed)
Non-healing wound, ulcer, or bone fracture
Other clinically significant disorders such as:\r\n* Active infection requiring systemic treatment within 28 days before the first dose of study treatment\r\n* Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment\r\n* History of organ transplant\r\n* Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment
Other clinically significant disorders such as:\r\n* Active infection requiring systemic treatment within 28 days before the first dose of study treatment\r\n* Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment\r\n* History of organ transplant\r\n* Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment\r\n* History of major surgery as follows:\r\n** Major surgery within 3 months of the first dose of cabozantinib if there were no wound healing complications or within 6 months of the first dose of cabozantinib if there were wound complications\r\n** Minor surgery within 1 month of the first dose of cabozantinib if there were no wound healing complications or within 3 months of the first dose of cabozantinib if there were wound complications\r\n* In addition, complete wound healing from prior surgery must be confirmed at least 28 days before the first dose of cabozantinib irrespective of the time from surgery
Serious, non-healing or dehiscing wound or active ulcer
Presence of a non-healing wound, non-healing ulcer, or bone fracture
Participant has a serious, non-healing wound, ulcer, or bone fracture
At least 4 weeks must have elapsed since any surgeries, with evidence of completed wound healing
Active wound, a serious or non-healing wound, an active ulcer or untreated bone fracture
Non-healing wound, bone fracture, or skin ulcer
mCRPC EXPANSION COHORT: Other clinically significant disorders such as:\r\n* Active infection requiring intravenous treatment within 7 days of starting protocol treatment\r\n* Serious non-healing wound/ulcer/bone fracture (excluding stable compression fracture) within 28 days before the first dose of study treatment
No evidence of a history of wound healing complications prior to study enrollment
Increased risk of wound dehiscence or presence of non-healing wounds
The patient has a serious or nonhealing wound, ulcer, or bone fracture within 28 days prior to enrollment
Serious, non-healing or dehiscing wound
Non-healing wound, ulcer, or bone fracture
REGORAFENIB EXCLUSION CRITERIA: Presence of a non-healing wound, non-healing ulcer, or bone fracture
Non-healing wound, active peptic ulcer or bone fracture
The patient has a serious or non-healing wound, ulcer, or bone fracture within 28 days prior to enrollment
Presence of a non-healing wound, non-healing ulcer, or benign bone fracture (patients with stress insufficiency fractures e.g. from osteoporosis or pathological fracture from tumor are eligible for study)
Serious or nonhealing wound, ulcer, bone fracture, or osteonecrosis of the jaw
Subject has a serious, non-healing wound, ulcer, or bone fracture
Incomplete wound healing
Presence of any non-healing wound, fracture, or ulcer
Must not exhibit a non-healing wound or any skin breakdown
Patients who have serious, non-healing wound, ulcer, or bone fracture
Major surgery or trauma within 28 days prior to first dose of pazopanib and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major surgery)
Serious, non-healing wound, active ulcer, or untreated bone fracture
Serious non-healing wound, ulcer, or bone fracture
Serious, non-healing wound, ulcer, or bone fracture
Serious non-healing wound, active peptic ulcer, or untreated bone fracture
Prior major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major)
Serious non-healing wound, non-healing ulcer, or bone fracture
Serious or non-healing wound, ulcer or bone fracture
The patient has a serious or non-healing wound, ulcer, or bone fracture within 28 days prior to first dose of protocol therapy
Serious, non-healing wound, active ulcer, or untreated bone fracture
A serious, non healing wound, ulcer, or bone fracture
Serious, non-healing wound, active ulcer, or untreated bone fracture; any bone fractures must be healed
Serious, non-healing wound, ulcer, or bone fracture
Non-healing wound(s) or ulcer(s) except for ulcerative lesions caused by the underlying neoplasm;
Non healing wound, ulcer or bone fracture
Non-healing serious wound, ulcer, or bone fracture unrelated to the primary tumor
Non?healing wound, ulcer, or bone fracture
Presence of a non-healing wound, non-healing ulcer, or bone fracture
Presence of a serious nonhealing wound, ulcer, or bone fracture
Ongoing significant, uncontrolled medical condition including: o Serious, non-healing wound, skin ulcer (of any grade), or bone fracture.
Other clinically significant disorders such as:\r\n* Active uncontrolled infection requiring intravenous systemic treatment within 14 days before the first dose of study treatment\r\n* Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment\r\n* History of organ transplant\r\n* Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment\r\n* History of major surgery as follows:\r\n** Major surgery within 3 months of the first dose of cabozantinib if there were no wound healing complications or within 6 months of the first dose of cabozantinib if there were wound complications\r\n** Minor surgery within 1 month of the first dose of cabozantinib if there were no wound healing complications or within 3 months of the first dose of cabozantinib if there were wound complications\r\n*** In addition, complete wound healing from prior surgery must be confirmed at least 28 days before the first dose of cabozantinib irrespective of the time from surgery
History of serious or non-healing wound, ulcer, or bone fracture
Evidence of inadequate wound healing
Patients with a non-healing wound, fracture, or ulcer
Non-healing wound, ulcer or bone fracture
Patients with serious non-healing wound, ulcer, or bone fracture within 28 days before registration; patients should not have had any major surgical procedures within 28 days of registration
Serious, non-healing wound, active ulcer, or untreated bone fracture
Other clinically significant disorders such as:\r\n* Active infection requiring systemic treatment\r\n* Serious non-healing wound/ulcer/bone fracture\r\n* History of organ transplant\r\n* Concurrent uncompensated hypothyroidism or thyroid dysfunction\r\n* History of major surgery within 4 weeks or minor surgical procedures within 1 week before randomization
Presence of a non-healing wound, non-healing ulcer, or bone fracture
Prior major surgery within the previous 28 days of study registration and/or presence of any non-healing wound, fracture, or ulcer
Subjects with a non-healing serious wound, ulcer, or bone fracture unrelated to the primary tumor
Patients who have a serious or non-healing wound, ulcer, or bone fracture at the time of study enrollment are not eligible
Serious or non-healing wound, ulcer or bone fracture
Serious non-healing wound, ulcer, bone fracture, or abscess
Serious, non-healing wound, ulcer, or bone fracture
Patients with a serious or non-healing wound, ulcer, or bone fracture are not eligible for this study
Patients with serious non-healing wound, ulcer, or bone fracture; this includes history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 28 days; patients with granulating incisions healing by secondary intention with no evidence of fascial dehiscence or infection are eligible but require weekly wound examinations
Serious, non-healing wound, ulcer, or bone fracture
Presence of a non-healing wound, non-healing ulcer, or bone fracture
The participant has a serious nonhealing: (a) wound, (b) peptic ulcer, or (c) bone fracture.
Serious, non-healing wound, infection, ulcer, bone fracture, or uncontrolled seizures
Patients with a serious or nonhealing wound, ulcer, or bone fracture within 28 days prior to enrollment
Patient must not have serious or non-healing wound, ulcer, or bone fracture at the time of randomization
Major surgery or trauma within 28 days prior to first dose of pazopanib and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major surgery)
Has evidence of inadequate wound healing.
Presence of any non-healing wound, fracture, or ulcer, or presence of symptomatic peripheral vascular disease
Patients are excluded if they have a non-healing wound or ulcer
Presence of non-healing wound, non-healing ulcer, or bone fracture.
Have had a serious or non-healing wound, ulcer, or bone fracture within 28 days prior to enrollment.
Serious non-healing wound, ulcer or bone fracture
Patients with serous non-healing wound, ulcer, or bone fracture.
Serious, non-healing wound, ulcer, or bone fracture requiring surgical intervention.
Presence of a non-healing wound, non-healing ulcer, or bone fracture
Serious non-healing wound, ulcer, or bone fracture
Serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture
Non-healing wound, ulcer or bone fracture
Presence of a non-healing wound, non-healing ulcer, or bone fracture.
Has history of a non-healing wound, ulcer, or bone fracture within 90 days (3 months) prior to entry in to the trial
Serious non-healing wound, ulcer, or bone fracture
Serious, non-healing wound, active ulcer, or untreated bone fracture as judged by treating physician
Serious, non-healing wound, ulcer, or bone fracture
Patients with a history of a serious non-healing wound, ulcer, or bone fracture are not eligible
Serious, non-healing wound, ulcer, or bone fracture
Serious or non-healing wound, active ulcer or bone fracture
Non-healing wound, ulcer or bone fracture
Serious, non-healing wound, ulcer, or bone fracture as so judged by the treating physician
Presence of a non-healing wound or non-healing ulcer that is not tumor related
Presence of any non-healing wound, fracture, or ulcer within 28 days prior to the first dose of study drug.
Other clinically significant disorders such as:\r\n* Active infection requiring systemic treatment within 28 days before the first dose of study treatment\r\n* Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment
Presence of a non-healing wound, non-healing ulcer, or bone fracture
Non-healing wound, ulcer, or bone fracture
Presence of any non-healing wound, fracture, or ulcer within 28 days prior to study registration.
Has a history of non-healing wounds or ulcers, or bone refractures within 3 months of fracture
Patients with serious non-healing wound, ulcer, or bone fracture
Serious or non-healing wound, ulcer, or bone fracture
Non-healing wound, ulcer, or bone fracture
Patients with serious non-healing wound, ulcer, or bone fracture, including history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 28 days; patients with granulating incisions healing by secondary intention with no evidence of fascial dehiscence or infection are eligible but require weekly wound examinations
Presence of a non-healing wound, non-healing ulcer, or bone fracture
Presence of a non-healing wound or non-healing ulcer that is not tumor related
Serious non-healing wound, ulcer, or bone fracture
Other clinically significant disorders such as:\r\n* Active infection requiring systemic treatment within 28 days before the first dose of study treatment\r\n* Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment\r\n* Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment
Ongoing serious, non-healing wound, ulcer, or bone fracture
Ongoing serious, non-healing wound, ulcer, or bone fracture
Serious or non-healing wound, skin ulcer, or bone fracture.
Major surgery or trauma within 28 days prior to first dose of study treatment and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major surgery)
Serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture
Participants who have non-healing wound, unhealed or incompletely healed fracture, or a compound (open) bone fracture at the time of enrollment
Prior major surgery or trauma within 28 days and/or presence of any non-healing wound, fracture or ulcer (procedures such as catheter placement not considered to be major)
Serious non-healing wound, ulcer, or bone fracture
Serious non-healing wound, ulcer, or bone fracture
Presence of a non-healing wound, non-healing ulcer, or bone fracture
Patients with a serious, non-healing wound, ulcer, or bone fracture are not eligible for participation
Non-healing wound, bone fracture or skin ulcer
Presence of a non-healing wound, non-healing ulcer, or bone fracture
No history of serious (i.e., requiring active medical therapy with medication or medical device under the supervision of a physician) non-healing wound, ulcer, trauma, or bone fracture within 28 days prior to study entry
Major surgery or trauma within 28 days prior to first dose of investigational product and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major surgery)
Non-healing wound, ulcer or fracture
Presence of a non-healing wound, non-healing ulcer, or bone fracture
Serious or non-healing wound, ulcer or bone fracture
History of a non-healing wound, ulcer, or bone fracture within 90 days (3 months) prior to registration
Patient must not have prior major surgery, trauma, presence of any non-healing wound, fracture, or ulcer within 28 days prior to first dose of study drug
Non-healing wound, ulcer (including gastrointestinal), or fracture
Serious or non-healing wound, ulcer or bone fracture; if patient develops a serious or non-healing wound, ulcer or bone fracture after enrollment, but prior to study drug initiation, patient is not eligible to begin protocol therapy
Non-healing wound, ulcer or bone fracture
No serious non-healing wound, ulcer or bone fracture
Prior major surgery or trauma within 28 days prior to registration and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major); if the patient has a compression fracture secondary to tumor this should be treated and 28 days elapsed prior to entry on the protocol
Prior major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major)
Serious, non-healing wound, active ulcer, or untreated bone fracture
Serious or non-healing wound, ulcer, or bone fracture
Serious, non-healing wound, active ulcer, or untreated bone fracture
Major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer not related to cancer (procedures such as catheter placement not considered to be major)
Other clinically significant disorders such as:\r\n* Active infection requiring systemic treatment\r\n* Serious non-healing wound/ulcer/bone fracture\r\n* History of organ transplant\r\n* Concurrent uncompensated hypothyroidism or thyroid dysfunction\r\n* History of major surgery within 4 weeks or minor surgical procedures within 1 week before randomization
History of serious or non-healing wound, ulcer, or bone fracture
Prior major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major)
Serious, non-healing wound, active ulcer, or untreated bone fracture
Serious, non-healing wound
Prior major surgery or trauma within 28 days prior to first dose of pazopanib and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major)
Patients with a history of non-healing wounds or ulcers, or bone refractures within 3 months of fracture
Non-healing wound, ulcer, or bone fracture
Patients with documented chronic non-healing wound, ulcer or bone fracture
Serious, non-healing wound, ulcer, or bone fracture; patients with any wound requiring surgical intervention (including scalp wounds requiring cranioplasty) will be allowed to resume the study if the wound is clean and without further infection post-surgical intervention
Subject has a serious, non-healing wound, ulcer, or bone fracture
Serious or non-healing active wound, ulcer, or bone fracture
Serious non-healing wound, active ulcer, or unhealed bone fracture.
Patients with serious non-healing wound, ulcer, or untreated bone fracture. This includes a history of abdominal fistula or gastrointestinal perforation within 6 months prior to Day 1. Patients with granulating incisions healing by secondary intention with no evidence of fascial dehiscence or infection are eligible but require weekly wound examinations until closure.
Serious or non-healing wound, ulcer or bone fracture
Serious, non-healing wound, ulcer, or bone fracture
Serious, non-healing wound, ulcer, or bone fracture
Non-healing wound, ulcer, or bone fracture.
Serious non-healing wound or ulcer on scalp
Severe acute infection; serious non-healing wound or ulcer on scalp
Presence of a non-healing wound, non-healing ulcer, or bone fracture
Presence of a non-healing wound, non-healing skin ulcer, or bone fracture
Presence of a non-healing wound or bone fracture
Prior major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major)
Serious, non-healing wound, active ulcer, or untreated bone fracture
Prior major surgery or trauma within 28 days prior to the protocol-mandated 4-week drug holiday and/or presence of any non-healing wound, fracture, or ulcer.
Patients with a serious non-healing wound ulcer, or bone fracture, or major surgical procedure within 21 days prior to starting treatment
Other clinically significant disorders such as:\r\n* Severe active infection requiring systemic treatment within 28 days before the first dose of study treatment\r\n* Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment\r\n* History of organ transplant\r\n* Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment (for asymptomatic patients with an elevated thyroid stimulating hormone [TSH], thyroid replacement may be initiated if clinically indicated without delaying the start of study treatment)\r\n* History of major surgery as follows:\r\n** Major surgery within 3 months of the first dose of cabozantinib; however, if there were no wound healing complications, patients with rapidly growing aggressive cancers, may start as soon as 6 weeks if wound has completely healed post-surgery\r\n** Minor surgery within 1 month of the first dose of cabozantinib if there were no wound healing complications or within 3 months of the first dose of cabozantinib if there were wound complications excluding core biopsies and Mediport placement\r\n* In addition, complete wound healing from prior surgery must be confirmed at least 28 days before the first dose of cabozantinib irrespective of the time from surgery
Non-healing wound, ulcer, or bone fracture.
Have a serious or nonhealing wound, peptic ulcer, or bone fracture within 28 days prior to receiving study drugs.
Serious, non-healing wound, ulcer, or bone fracture.
Uncontrolled diabetes, active liver disease, poorly controlled chronic obstructive pulmonary disease, serious or non-healing wound, ulcer, or fracture;
Serious, non-healing wound, ulcer, or bone fracture
Severe, nonhealing or open wound, active ulcer, or untreated bone fracture
Serious and non-healing wound, active ulcer, or untreated bone fracture.
Non-healing wound, ulcer, or bone fracture
Patients must not have a non-healing wound or fracture
Presence of any non-healing wound, fracture, or ulcer
Non-healing wound, skin ulcer, or bone fracture
Any medical condition that requires intact wound healing capacity and is expected to endanger participant safety if wound healing capacity would be severely reduced during administration of the investigational agent
Serious or non-healing wound, active ulcer, or untreated bone fracture
Serious, non-healing wound, skin ulcer (of any grade), or bone fracture.
Presence of a non-healing wound, non-healing ulcer, or bone fracture
Serious, non-healing wound, ulcer, or bone fracture
Serious or non-healing active wound, ulcer, or bone fracture
Ongoing serious non-healing wound, ulcer, or bone fracture
Non-healing wound, ulcer (including gastrointestinal), or fracture
Serious, non-healing wound, active ulcer, or untreated bone fracture; bone fractures must be healed
Evidence of significant uncontrolled concomitant diseases, such as cardiovascular disease, nervous system, pulmonary, renal, hepatic, endocrine, or gastrointestinal disorders; or a serious non-healing wound or fracture
Prior major surgery or trauma within 28 days prior to the first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer.
Serious non-healing wound, ulcer, or bone fracture
Serious non-healing wound, ulcer, or active bone fracture;
Serious or non-healing wound, ulcer, or bone fracture
Has had a serious nonhealing wound, ulcer, or bone fracture within 4 weeks prior to randomization
Serious nonhealing wound, ulcer, or bone fracture within 28 days prior to randomization
Patients with serious non-healing wound, ulcer or bone fracture; this includes history of abdominal fistula or intra-abdominal abscess within 6 months; patients with granulating incisions healing by secondary intention with no evidence of fascial dehiscence or infection are eligible but require weekly wound examinations
Prior major surgery or trauma within 14 days of the first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer
Serious non-healing wound, ulcer, or bone fracture
Incomplete wound healing
A serious, non-healing wound, ulcer, or bone fracture
Major surgery or trauma within 28 days prior to first dose of investigational product and/or presence of any non-healing wound, fracture, or ulcer
Major surgery or trauma within 29 days prior to first dose of study drug and/or presence of any non-healing wound, fracture or ulcer (catheter placement is not major surgery)
Patients who have not recovered from the surgical resection of rectal cancer such as wound dehiscence, non-healing wound, wound infection and fistula
Serious, non-healed wound, ulcer, or bone fracture
No history of serious non-healing wound, ulcer, or bone fractures
Serious, non-healing or dehiscing wound or active ulcer
Any serious or non-healing wound, ulcer, or bone fracture
Serious, non-healing wound, active ulcer, or unhealed bone fracture
Presence of a non-healing wound, non-healing ulcer, or bone fracture
Serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture
Patients with serious, non-healing wound, ulcer or bone fracture (other than pathologic fracture)
Serious, non-healing or dehiscing wound or active ulcer
History of recent fracture (within 3 months of recruitment), complicated non-healing fracture, hip arthroplasty, knee arthroplasty
Patient must not have prior major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major)
Patient must not have a serious or non-healing wound, ulcer, or bone fracture